Minodronic acid (hydrate)

Minodronic acid (YM-529) hydrate is a third-generation bisphosphonate that directly and indirectly prevents proliferation, induces apoptosis, and inhibits metastasis of various types of cancer cells. Minodronic acid (YM-529) is an antagonist of purinergic P2X2/3 receptors involved in pain[1][2].

Product Specifications

CAS Number

[155648-60-5]

Product Name Alternative

YM-529 (hydrate)

UNSPSC

12352005

Hazard Statement

H301, H361

Target

Apoptosis; P2X Receptor

Type

Reference compound

Related Pathways

Apoptosis; Membrane Transporter/Ion Channel

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/minodronic-acid-hydrate.html

Purity

99.67

Solubility

1 M NaOH : ≥ 100 mg/mL|H2O : 20 mg/mL (ultrasonic; adjust pH to 9 with 1 M NaOH)

Smiles

OC(P(O)(O)=O)(P(O)(O)=O)CC1=CN=C2C=CC=CN21.O

Molecular Formula

C9H14N2O8P2

Molecular Weight

340.16

Precautions

H301, H361

References & Citations

[1]Sato K, et al. A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo. Br J Cancer. 2006 Nov 20;95 (10) :1354-61.|[2]Tanaka M, et al. Minodronic acid induces morphological changes in osteoclasts at bone resorption sites and reaches a level required for antagonism of purinergic P2X2/3 receptors. J Bone Miner Metab. 2018 Jan;36 (1) :54-63.